A cutting edge overview: psoriatic disease
- PMID: 22359072
- DOI: 10.1007/s12016-012-8309-z
A cutting edge overview: psoriatic disease
Abstract
Psoriasis is a lifelong skin disease, affecting about 2% of the global population. Generalized involvement of the body (erythroderma), extensive pustular lesions, and an associated arthritis known as psoriatic arthritis (PsA) are severe complications of psoriasis. Genetic, immunologic, and environmental factors contribute to its pathogenesis. A complete understanding of the pathogenesis of psoriasis and psoriatic arthritis is lacking. Cytokines, chemokines, adhesion molecules, growth factors like NGF, neuropeptides, and T cell receptors all act in an integrated way to evolve into unique inflammatory and proliferative processes typical of psoriasis and PsA. Management of psoriasis requires exemplary skin care along with careful monitoring of arrays of comorbidities which includes arthritis and coronary artery disease. In many ways, psoriasis can be considered a model autoimmune disease. This statement itself is ironic considering that it was not recognized as immune mediated until relatively recently. Fortunately, the immunobiology has made enormous strides and there are now excellent therapeutic options for patients. In this thematic review, we have attempted to provide summaries of not only basic science and clinical research, but also an overview of future research directions.
Similar articles
-
T cell responses in psoriasis and psoriatic arthritis.Autoimmun Rev. 2015 Apr;14(4):286-92. doi: 10.1016/j.autrev.2014.11.012. Epub 2014 Nov 28. Autoimmun Rev. 2015. PMID: 25445403 Review.
-
Tissue-Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis.Arthritis Rheumatol. 2021 Jul;73(7):1220-1232. doi: 10.1002/art.41652. Epub 2021 May 25. Arthritis Rheumatol. 2021. PMID: 33452865 Free PMC article.
-
Animal models of psoriasis and psoriatic arthritis: an update.Curr Rheumatol Rep. 2006 Oct;8(5):342-7. doi: 10.1007/s11926-006-0063-x. Curr Rheumatol Rep. 2006. PMID: 16973107 Review.
-
Psoriatic Arthritis with Annular Pustular Psoriasis.Intern Med. 2016;55(5):519-21. doi: 10.2169/internalmedicine.55.5535. Epub 2016 Mar 1. Intern Med. 2016. PMID: 26935375
-
Immune regulation in psoriasis and psoriatic arthritis--recent developments.Immunol Lett. 2007 Dec 15;114(2):59-65. doi: 10.1016/j.imlet.2007.08.009. Epub 2007 Sep 25. Immunol Lett. 2007. PMID: 17928070 Review.
Cited by
-
Effects of Autophagy Modulators and Dioxin on the Expression of Epidermal Differentiation Proteins on Psoriasis-Like Keratinocytes in vitro and ex vivo.Clin Cosmet Investig Dermatol. 2022 Jun 23;15:1149-1156. doi: 10.2147/CCID.S368105. eCollection 2022. Clin Cosmet Investig Dermatol. 2022. PMID: 35769934 Free PMC article.
-
Psoriasis and Cardiovascular Risk: Assessment by CUORE Project Risk Score in Italian Patients.Dermatol Res Pract. 2013;2013:389031. doi: 10.1155/2013/389031. Epub 2013 Sep 8. Dermatol Res Pract. 2013. PMID: 24082881 Free PMC article.
-
S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis.J Immunol Res. 2014;2014:696415. doi: 10.1155/2014/696415. Epub 2014 May 14. J Immunol Res. 2014. PMID: 24955375 Free PMC article.
-
Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.Clin Rheumatol. 2015 Jun;34(6):1019-23. doi: 10.1007/s10067-015-2961-7. Epub 2015 May 5. Clin Rheumatol. 2015. PMID: 25939522 Review.
-
Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies.Mediators Inflamm. 2018 Feb 12;2018:2403935. doi: 10.1155/2018/2403935. eCollection 2018. Mediators Inflamm. 2018. PMID: 29670461 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous